<?xml version="1.0" encoding="UTF-8"?>
<p id="Par30">In the open commentary, one panelist recommended adding the following statement: 
 <italic>Incidental (secondary) findings of clinically actionable, validated genomic results should be made available</italic>. Six statements were retained for re-rating in Round 2 (#5–7, #10–12), as well as requests for amendments to four statements (#7, #10–12). The new Statement (#13) regarding return of incidental findings was also put to a panel vote during Round 2.
</p>
